168 related articles for article (PubMed ID: 35091270)
41. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
42. An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A; Sonneveld P
Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
[TBL] [Abstract][Full Text] [Related]
43. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
Jurczyszyn A; Zawirska D; Skotnicki AB
Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
[TBL] [Abstract][Full Text] [Related]
44. A clinical perspective on plasma cell leukemia; current status and future directions.
Tuazon SA; Holmberg LA; Nadeem O; Richardson PG
Blood Cancer J; 2021 Feb; 11(2):23. PubMed ID: 33563906
[TBL] [Abstract][Full Text] [Related]
45. Advances and practical use of monoclonal antibodies in multiple myeloma therapy.
Lee HC; Weber DM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):512-520. PubMed ID: 27913523
[TBL] [Abstract][Full Text] [Related]
46. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
Fernández de Larrea C; Kyle RA; Durie BG; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; LeLeu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist UH; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Bladé J; Orlowski RZ; Shah JJ;
Leukemia; 2013 Apr; 27(4):780-91. PubMed ID: 23288300
[TBL] [Abstract][Full Text] [Related]
47. Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents.
Lemieux C; Johnston LJ; Lowsky R; Muffly LS; Craig JK; Shiraz P; Rezvani A; Frank MJ; Weng WK; Meyer E; Shizuru J; Arai S; Negrin R; Miklos DB; Sidana S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):e328-e332. PubMed ID: 32961371
[TBL] [Abstract][Full Text] [Related]
48. Single-Center Experience of Patients with Plasma Cell Leukemia in the Era of New Therapeutics.
Dampmann M; Flossdorf S; Keyl J; Reinhardt HC; Hanoun C
Acta Haematol; 2024 May; ():1-8. PubMed ID: 38763126
[TBL] [Abstract][Full Text] [Related]
49. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
50. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
Nishida H; Yamada T
J Oncol; 2019; 2019():6084012. PubMed ID: 31781214
[TBL] [Abstract][Full Text] [Related]
51. Monoclonal antibodies in multiple myeloma.
Vozella F; Fazio F; Lapietra G; Petrucci MT; Martinelli G; Cerchione C
Panminerva Med; 2021 Mar; 63(1):21-27. PubMed ID: 32955188
[TBL] [Abstract][Full Text] [Related]
52. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea C; Kyle R; Rosiñol L; Paiva B; Engelhardt M; Usmani S; Caers J; Gonsalves W; Schjesvold F; Merlini G; Lentzch S; Ocio E; Garderet L; Moreau P; Sonneveld P; Badros A; Gahrton G; Goldschmidt H; Tuchman S; Einsele H; Durie B; Wirk B; Musto P; Hayden P; Kaiser M; Miguel JS; Bladé J; Rajkumar SV; Mateos MV
Blood Cancer J; 2021 Dec; 11(12):192. PubMed ID: 34857730
[TBL] [Abstract][Full Text] [Related]
53. [Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].
Tamura H
Rinsho Ketsueki; 2018; 59(10):2169-2177. PubMed ID: 30305523
[TBL] [Abstract][Full Text] [Related]
54. Primary plasma cell leukemia 2.0: advances in biology and clinical management.
Neri A; Todoerti K; Lionetti M; Simeon V; Barbieri M; Nozza F; Vona G; Pompa A; Baldini L; Musto P
Expert Rev Hematol; 2016 Nov; 9(11):1063-1073. PubMed ID: 27759436
[TBL] [Abstract][Full Text] [Related]
55. Primary Plasma Cell Leukemia: Identity Card 2016.
Musto P; Simeon V; Todoerti K; Neri A
Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
[TBL] [Abstract][Full Text] [Related]
56. Plasma cell leukemia: a rare condition.
Jiménez-Zepeda VH; Domínguez VJ
Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
[TBL] [Abstract][Full Text] [Related]
57. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
Piggin A; Prince HM
Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
[TBL] [Abstract][Full Text] [Related]
58. Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
Delforge M; Vlayen S; Kint N
Expert Rev Hematol; 2021 Apr; 14(4):365-376. PubMed ID: 33733978
[No Abstract] [Full Text] [Related]
59. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia.
Parrondo RD; Moustafa MA; Reeder C; Sher T; Roy V; Muchtar E; Warsame R; Alegria V; Gonsalves W; Dingli D; Hayman S; Kapoor P; Chanan-Khan AA; Ailawadhi S
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):355-360. PubMed ID: 33563579
[No Abstract] [Full Text] [Related]
60. Monoclonal Antibodies in Myeloma: Optimizing Targeted Therapy.
Hartley-Brown M; Chitty D; Thakur R
Cancer J; 2021 May-Jun 01; 27(3):222-230. PubMed ID: 34549911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]